By 
GSK PLC
GSK,
-0.64%
said Monday that the U.S. Food and Drug Administration has approved Boostrix for immunization during the third trimester of pregnancy to help prevent pertussis, or whooping cough, in infants under two months old.
The U.K.-based maker of cancer and asthma medications said the vaccine–which is given during pregnancy–passes antibodies to babies before birth. The vaccine is also indicated against tetanus, diphtheria and pertussis in individuals aged 10 years and older, GSK said.
Boostrix is currently approved in more than 80 countries including most EU countries, as well as Canada, Australia and New Zealand, as a vaccine for tetanus, diphtheria and pertussis, the company said.
Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com
Comments